Intravenous granisetron for food protein-induced enterocolitis syndrome in Japanese children: A retrospective study
Abstract
BACKGROUND: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated gastrointestinal food allergy characterized by delayed-onset vomiting. Although ondansetron has demonstrated efficacy in managing FPIES-related symptoms, its use remains off-label in Japan. Granisetron hydrochloride (GH), another 5-HT3 receptor antagonist, is approved in Japan for postoperative and chemotherapy-induced nausea and vomiting in children and is widely used in pediatric clinical settings. However, its use in FPIES has not been fully evaluated. This study aimed to assess the effectiveness and safety of intravenous GH in Japanese children undergoing oral food challenges (OFCs) for FPIES.
METHODS: This retrospective study included pediatric patients who underwent OFCs for suspected or confirmed FPIES between January 2019 and September 2024 at a single center in Japan. Patients who developed vomiting received intravenous GH (40 μg/kg) and were subsequently monitored for symptom resolution, recurrence, the need for additional interventions, and any adverse events.
RESULTS: Among the 73 OFCs performed in 50 patients, 20 (27.4%) yielded a positive result, defined by the occurrence of vomiting. Of these, 18 cases from 16 patients received intravenous GH, and 16 OFCs from 14 patients were included in the final analysis. Vomiting resolved completely in 12 cases (75.0%), while four (25.0%) experienced only one additional vomiting episode. No cases required further antiemetic therapy or…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 50 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.